Glucosylceramide, derived from cancer cells, induces unconventional UPR in macrophages by altering lipid composition and saturation on ER membranes, activating IRE1‐mediated splicing XBP1 production and STAT member 3 (STAT3) activation. The gene discussed is XBP1; the disease is cancer.